Environmental

KPTI’s very high R&D intensity versus revenue suggests a comparatively resource-heavy operating model, but peers in biotech often show similarly elevated development footprints.

The company’s capital allocation appears research-led rather than manufacturing-led, which limits direct emissions exposure relative to industrial peers but not versus biotech peers.

No filing-based evidence provided on energy, waste, or climate targets prevents a stronger environmental assessment, leaving positioning broadly in line with disclosure-light peers.

Overall environmental positioning appears moderate because the available metrics indicate typical biotech resource use without clear evidence of peer-leading environmental management.

Social

Stock-based compensation at roughly 8% of revenue indicates moderate dilution pressure, which is common in biotech but still weaker than peers with tighter compensation discipline.

High R&D intensity can support patient-focused innovation and scientific talent retention, yet the metric alone does not demonstrate superior workforce or community outcomes versus peers.

No provided evidence on clinical trial safety, product access, or employee turnover limits confidence in a stronger social ranking relative to peer disclosures.

Social positioning is moderate because the available data show standard biotech talent economics, but not a clearly differentiated stakeholder record versus peers.

Governance

Negative leverage ratios imply net cash rather than debt, which reduces balance-sheet governance risk and compares favorably with leveraged peers.

Stock-based compensation remains a governance consideration, but the reported level is not unusually high for development-stage biotech companies.

The absence of filing evidence on board independence, executive pay design, and shareholder rights limits a higher governance score despite the conservative leverage profile.

Governance positioning is moderately positive because low leverage supports oversight quality, although disclosure gaps prevent a stronger peer-relative assessment.

Overall Score

KPTI’s ESG positioning is broadly average versus biotech peers, with low leverage supporting governance while limited disclosure and standard biotech resource intensity cap upside.

Score Driver: Low Net Leverage Relative To Peers